Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03737708
- Locations
- 🇰🇷
Site KR82003, Daegu, Korea, Republic of
🇰🇷Site KR82007, Daegu, Korea, Republic of
🇰🇷Site KR82002, Incheon, Korea, Republic of
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
- Conditions
- Interventions
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 140
- Registration Number
- NCT03714022
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸PPD Development, LP, Austin, Texas, United States
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Dimitrios Tzachanis, MD PhD
- Target Recruit Count
- 43
- Registration Number
- NCT03680092
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Safety and Efficacy of Abatacept in IgG4-Related Disease
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03669861
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Rheumatoid Arthritis Memory B Cells and Abatacept
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 25
- Registration Number
- NCT03652961
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 34
- Registration Number
- NCT03632187
- Locations
- 🇫🇷
CHRU de Brest, Brest, France
🇫🇷CH de Morlaix, Morlaix, France
🇫🇷CH St-Malo, Saint-Malo, France
Effects of Abatacept on Myocarditis in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 11
- Registration Number
- NCT03619876
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT03492658
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 2500
- Registration Number
- NCT03440892
- Locations
- 🇸🇪
Dept of Rheumatology and Inflammation research, Gothenburg, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.